Portal de investigación
SEOM clinical guidelines for the treatment of Hodgkin's lymphoma
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rueda Domínguez A
- Alfaro Lizaso J
- de la Cruz Merino L
- Gumá I Padró J
- Quero Blanco C
- Llanos Muñoz M
- Martinez Banaclocha N
- Rodriguez Abreu D
- Provencio Pulla M
Grupos
Abstract
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10-15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 1005-1013
- PubMed:
- 26497354
- Factor de Impacto:
- 0,865 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 4
Documentos
- No hay documentos
Filiaciones
Keywords
- Oncohematology malignancies; Hodgkin lymphoma; Hodgkin lymphoma therapy
Campos de Estudio
Cita
Rueda A,Alfaro J,de la Cruz L,Gumá I Padró J,Quero C,GÓMEZ J,Llanos M,Martinez N,Rodriguez D,Provencio M. SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. Clin. Transl. Oncol. 2015. 17. (12):p. 1005-1013. IF:2,075. (3).